225-OR: Key Role for Glucose-Alanine Cycling in the Regulation of Hepatic Mitochondrial Oxidation during Starvation in Humans

Abstract

Listen

Translate article

We examined whether starvation alters rates of hepatic mitochondrial oxidation in humans by applying a novel 13C Positional Isotopomer NMR Tracer Analysis (PINTA) method to assess rates of hepatic mitochondrial oxidation in healthy volunteers (n=15) following an overnight (12h) and a 60h fast. A 3h intravenous infusion of [3-13C] lactate (4.3 μmol/Kg-min), [1,2,3,4,5,6,6-2H7] glucose (0.22 μmol/Kg-min), and [13C4]-β-hydroxybutyrate (BOHB) (0.01 mg/Kg-min) was administered and blood was collected for GC-MS, LC-MS/MS and 13C MRS PINTA analyses. Following the 60h fast rates of endogenous glucose production decreased by 27% (p=0.0002) and rates of hepatic mitochondrial oxidation decreased by 52% (p=0.0014) whereas rates of hepatic pyruvate carboxylase flux remained unchanged. To ascertain whether decreased rates of alanine turnover during starvation play a role in promoting decreased rates of hepatic mitochondrial oxidation we infused [3-13C] alanine in a subgroup (n=5) of subjects and found that 60h of fasting promoted a 28% reduction in alanine turnover (p=0.044 vs. 12h fast). In order to determine whether this reduction in alanine turnover was responsible for the reduced rates of hepatic mitochondrial oxidation we infused unlabeled alanine to a subgroup (n=9) of the 15 subjects in a repeat 60h fasting study to increase rates of alanine turnover to rates measured after 12h of fasting and found that this perturbation increased rates of hepatic mitochondrial oxidation by 63% (p=0.009 vs. 60h fast) to rates similar to the 12h fasting state (60h+ala: 232±21 vs. 12h: 295±44 μmol/min, p=0.303). Conclusion: These studies demonstrate that 60h of starvation in humans induces marked reductions in rates of hepatic mitochondrial oxidation, which in turn can be attributed to reduced rates of glucose-alanine cycling. Disclosure K. Petersen: Advisory Panel; Spouse/Partner; Aegerion Pharmaceuticals, AstraZeneca, AstraZeneca, Janssen Research & Development, Merck & Co., Inc., Novo Nordisk A/S. Consultant; Spouse/Partner; Gilead Sciences, Inc. Consultant; Self; Merck & Co., Inc. Consultant; Spouse/Partner; Nimbus Discoverey. Consultant; Self; Novo Nordisk A/S. S. Dufour: None. G. Cline: None. G.I. Shulman: Advisory Panel; Self; AstraZeneca, Janssen Research & Development, Merck & Co., Inc. Advisory Panel; Spouse/Partner; Merck & Co., Inc. Board Member; Self; Novo Nordisk A/S. Consultant; Self; Aegerion Pharmaceuticals, IMetabolic BioPharma Corporation, Longitude Capital, Nimbus Discovery, Inc., Staten Biotechnology B.V. Funding National Institutes of Health